Stage 4 Hepatic (Liver) Cancer Treatment
Overcoming Late-Stage Hepatic (Liver) Cancer with Advanced Treatment Options
For the last 20 years, patients diagnosed with early and late-stage liver cancer have turned to Integrative Cancer Centers of America, a center of excellence for personalized oncology, to receive a personalized and genetically driven approach to care that we believe gives our patients a greater chance to achieve positive outcomes. We have achieved success by combining years of collective research and clinical experience treating the most difficult and complex cancer diagnoses by utilizing powerful targeted personalized treatments. We often hear from our patients, that they wish they had found us sooner. We feel that speaks volumes to the type of precision care patients should be receiving.
Liver cancer is one of the most common cancers worldwide and despite the many advancements in prevention, screening, diagnostics, and treatment; incidences and deaths from primary liver cancer continue to climb in the standardized treatment model  . Unfortunately, standard hepatic cancer treatment protocols are estimated to be curative in less than 20% of primary liver cancer patients . Most patients only receive palliative treatment meant to optimize quality of life and mitigate suffering . Standardized oncology focuses on management of symptoms, as opposed to achieving remission, because conventional radiotherapy and chemotherapy are often ineffective long term with liver cancers . Especially late-stage liver cancers that have metastasized add multiple other complications to treatment.
Patients deserve a precision approach that better accounts for the individuals' unique tumor biology targets and immunotherapy targets to come against cancer's progression in far more detailed and comprehensive manner. With nearly two decades of clinical experience, Integrative Cancer Centers of America has been able to overcome many of the challenges associated with hepatic cancer treatment planning. By providing customizable advanced integrative treatment options and procedures that go beyond the standardized options, ICCA has been able to out preform many renowned cancer treatment centers.
Understanding and Fighting the Cause of Hepatocellular Carcinoma (HCC)
The most common primary liver cancer is Hepatocellular carcinoma (HCC). Patients suffering from HCC only have access to suboptimal care in the conventional medical system . This is unfortunate because HCC is on the rise worldwide  and in the United States alone, an estimated 42,000 adults were diagnosed with primary liver cancer in 2020 . Treating the root causes of cancer is a key focus at ICCA. We have seen clinically that addressing the causative factors, in combination with our precision treatment modalities, gives our patients the best possible chance to maintain lasting results against their disease. If the cause of the cancer is not properly addressed, then the likelihood of recurrence is much higher. Hepatitis, for instance, is a major risk factor for developing HCC. More than 70% of HCC cases worldwide are correlated with chronic hepatitis B and C .
Without comprehension of the mechanisms that may have led to the development of the cancer, other cancer treatment facilities may not possess the expertise to understand and effectively treat the chronic conditions that may be feeding the cancer's continued growth and spread. Fortunately, at ICCA, we specialize in treating complex late-stage cancers in addition to chronic infections. We have developed proprietary technology and clinical expertise that gives us a decided edge in understanding and treating Hepatocellular carcinoma caused by chronic infections.
ICCA is extremely experienced in identifying and treating the infectious causes of cancer. We have performed and continue to carry out extensive research into the topic and have even published on the various correlations between infectious diseases and cancer. Our dedication to research shows how uniquely qualified and experienced ICCA is at treating not only late-stage progressive cancer, but also chronic infections and the complex connection between the two. Viruses like hepatitis can affect the genes in a cell as well as potentially deregulate tumor suppression and oncogene expression . In addition, hepatitis facilitates pro-inflammatory cytokines that creates a perfect environment for caner growth . By incorporating inflammatory marker, oncogene downregulation, tumor suppressor gene upregulation, and immunotherapy; ICCA provides a comprehensive approach that accounts for the multiple variables that combine to form each patient's unique cancer blueprint. It is not enough to treat liver cancer alone, being able to effectively combat the chronic infections and any other mitigating cancer-causing factors is pivotal for providing a comprehensive cancer treatment.
CIPI ™ Treatment for Liver Cancer
CIPI ™, or Chemo Immunotherapy Percutaneous Injections, is a proprietary form of tumor embolization that ICCA utilizes to treat tumors that may be inoperable or difficult to penetrate. CIPI ™ is extremely useful for treating liver cancer because it can circumvent factors that traditionally make this cancer extremely hard to treat. Not only is liver cancer often inoperable, but liver cancer can form a thick stroma around the tumor that resists penetration by normal chemotherapy methods. Unlike other tumor embolization methods, CIPI ™ takes the precision a step further by directly injecting targeted chemotherapy and adjunctive immune modulating agents into the tumor through a thin catheter for precision absorption of the medication directly into the tumor. This method allows ICCA's custom medications to effectively bypass the thick stroma while providing optimal therapeutic absorption. However, CIPI ™ goes beyond tumor embolization and can create a systemic immune response that works to attack metastasized cancer cells in addition to destroying solid tumors.
By utilizing customized protocols of genetically targeted medications, ICCA creates a personalized treatment plan custom designed for each patient's unique cancer presentation. ICCA designs this customized protocol through a proprietary algorithm that combines information on immune markers, oncogenes, cancer antigens, and chemosensitivity. With help from the algorithm, ICCA's experienced doctors choose the precision targeted chemotherapies, immunotherapies, and natural agents for each individual patient's specific needs. During the CIPI ™ procedure, these agents are injected directly into the tumor through the arterial blood supply to contain and focus the agents on the tumor itself. These agents go to work embolizing the solid tumor over multiple treatments.
From there, CIPI ™ works by involving the immune system to fight metastasized cancer cells throughout the body as well. After the tumor is embolized by the CIPI ™ treatment, antigens from the destroyed tumor can be used by the body to target free floating cancer cells. The systemic immune response caused by the CIPI procedure is an important factor that helps treat beyond the solid tumor causing an immune cascade throughout the body. The majority of the patients we see at ICCA are diagnosed with a late-stage form of liver cancer and treating the solid tumor alone is not going to be enough to address their complete disease. CIPI ™ allows us to treat the hard to reach solid tumors while also addressing the metastasized free-floating cancer cells in the body. The goal with CIPI ™ is not just to kill the tumor but to comprehensively treat cancer wherever it may spread.
ICCA Specializes in Late Stage Cancer Treatment
Hepatocellular carcinoma, and other liver cancers, cause symptoms like weight loss, loss of appetite, and fatigue; because these symptoms are so vague and broad many liver cancer patients are not diagnosed until the disease has progressed and the prognosis has become unfavorable. Integrative Cancer Centers of America specializes in treating late-stage and complex cancers; our clinical experience has shown us that a personalized treatment protocol is even more important in the later stages of cancer. Cancer is a genetic disease that differs wildly from patient to patient. With the conventional approach, these unique differences are not accounted for; and cancer is treated based on type and stage instead of your unique epigenetics and cancer biomarkers. Furthermore, the standard approach of cancer treatment utilizes maximum allowable doses of chemotherapy that has the potential to destroy a patient's immune system, when not targeted properly, which can lead to further progression of disease. Through a form of micro-dosed genetically targeted chemotherapy and advanced immunotherapies, Integrative Cancer Centers of America provides a completely customized treatment protocol that comprehensively builds the immune system and attacks the cancer to create a multifaceted approach. The immune system is the first line of defense against cancer and is one of the greatest weapons for cancer treatment. Conventional medicine largely ignores the immune systems importance and untargeted chemotherapy can further deteriorate the patient's immune system. By restoring the immune system first and foremost, ICCA activates one of the greatest weapons against cancer and improves the viability of further treatment.
While some patients may find success with conventional treatment methods, the vast majority of patients we treat at ICCA have already exhausted the traditional methods and are looking for a more advanced precision-based approach. Our clinical experience with liver cancer and other inoperable tumors has led to the development of specialized treatment options and procedures that we find to potentially be beneficial for our patient base. ICCA offers a synergetic approach that combines superior genetic targeting, proprietary CIPI ™ delivery, and advanced immunotherapies that no other clinic in the world can offer. Contact one of our patient care educators today, to see if we can improve your cancer treatment plan. We are looking forward to hearing from you, and we wish you the best of health!
 Knawy, B.A., L. Bolondi, and K.R. Reddy, Hepatocellular Carcinoma : A Practical Approach. 2009, Baton Rouge, UNITED STATES: CRC Press LLC.
 Balogh, J., et al., Hepatocellular carcinoma: a review. Journal of hepatocellular carcinoma, 2016. 3: p. 41-53.
 Qiao, L., Y. Li, and X. Yan, Molecular Aspects of Hepatocellular Carcinoma. 2012: Bentham Science Publishers.
 Williams, R., S.D. Taylor-Robinson, and S.D. Taylor-Robinson, Clinical Dilemmas in Primary Liver Cancer. 2011, Hoboken, UNITED KINGDOM: John Wiley & Sons, Incorporated.
 American Cancer Society. Key Statistics About Liver Cancer. 2020; Available from: https://www.cancer.org/